Subscribe

Ilyang Pharmaceutical Co.,Ltd (007570.KS)

KRW8,220.00 -10.00 (-0.12%)
KR KSC Healthcare Drug Manufacturers - Specialty & Generic
Address 110, Hagal-ro 17096
Yongin, KR
CEO Dong-Yeon Kim
Website ilyang.co.kr
IPO 2000-01-04
ISIN KR7007570005

Explore sections of this company profile

Also trades on Korea Exchange · 007570.KS (KRW) Korea Exchange · 007575.KS (KRW)
Description

Headquartered in Yongin, South Korea, Ilyang Pharmaceutical Co.,Ltd is a prominent pharmaceutical enterprise that has been operating since its establishment in 1946. The company, which was formerly known as Il-Yang Pharm. Ind. Co. until its renaming in May 1991, primarily conducts its business in South Korea. It develops and provides a comprehensive portfolio of medicines addressing various therapeutic areas, such as oncology, cardiovascular health, endocrine and metabolic conditions, women's health (including female hormone treatments and cheonjiyang), urology, ophthalmology, liver diseases, pain and inflammation, digestive system issues, dermatological complaints, and respiratory illnesses. Their pharmaceutical offerings also extend to nutrient infusions, neurological medications, antibiotics, antifungals, insecticides, and vaccines. In addition to medicinal products, Ilyang manufactures a range of consumer health items, including health drinks, dietary supplements, health foods, cosmetics, and other beverages. The company is also a producer of numerous pharmaceutical raw materials, specifically various aluminum and magnesium compounds. Ilyang Pharmaceutical has an international footprint, exporting its diverse product range to roughly 14 countries worldwide.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
KRW8,220.00 -10.00 (-0.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
78.9K
Beta
0.42
Float Shares
14.05M
Free Float %
78.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.61% -1.30% -16.82% -24.60% -24.60% -24.60% -23.24% -43.19% -74.44% -80.08% +60.52%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
8,220.00
Ratings Trend (MoM) 100% Bullish
Rating 2024-11 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.40
Distress
Piotroski F-Score
7 / 9
Strong
MOAT Score
0 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +1.3% Q1'26: +5.0% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -32.6% Q1'26: +407.4% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -4.0% Q1'26: +40.4% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +1.8% Q1'26: -11.3% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +0.9% Q1'26: -8.4% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +6.1% Q1'26: -6.2% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    9.53× Q1'26: -5.31× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.55) × ERP
WACC = 61% × Ke + 39% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 8,220.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2014
actual 		Dec 2015
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana. 		Dec 2031
1 Rev. Ana.
1 EPS Ana.
Revenue
147.73B
est: 210.00B (-29.7%)
211.80B
est: 249.10B (-15.0%)
186.29B
est: 249.10B (-25.2%)
261.61B
est: 264.00B (-0.9%)
269.81B
est: 280.70B (-3.9%)
300.04B
est: 295.00B (+1.7%)
324.57B
est: 328.00B (-1.0%)
343.33B
est: 357.20B (-3.9%)
371.35B
est: 398.50B (-6.8%)
268.86B
est: 210.00B (+28.0%)
272.24B
est: 249.10B (+9.3%)
264.00B
264.00B – 264.00B
+6.0% YoY
280.70B
280.70B – 280.70B
+6.3% YoY
295.00B
295.00B – 295.00B
+5.1% YoY
328.00B
328.00B – 328.00B
+11.2% YoY
357.20B
357.20B – 357.20B
+8.9% YoY
398.50B
398.50B – 398.50B
+11.6% YoY
EBITDA
16.27B
est: 21.48B (-24.3%)
17.40B
est: 25.48B (-31.7%)
25.33B
est: 25.48B (-0.6%)
33.05B
est: 27.00B (+22.4%)
97.71B
est: 28.71B (+240.3%)
20.33B
est: 30.18B (-32.6%)
39.09B
est: 33.55B (+16.5%)
38.47B
est: 36.54B (+5.3%)
48.44B
est: 40.76B (+18.8%)
25.03B
est: 18.83B (+33.0%)
13.31B
est: 22.33B (-40.4%)
23.67B
23.67B – 23.67B
+6.0% YoY
25.17B
25.17B – 25.17B
+6.3% YoY
26.45B
26.45B – 26.45B
+5.1% YoY
29.41B
29.41B – 29.41B
+11.2% YoY
32.03B
32.03B – 32.03B
+8.9% YoY
35.73B
35.73B – 35.73B
+11.6% YoY
EBIT
11.11B
est: 16.41B (-32.3%)
6.74B
est: 19.46B (-65.4%)
15.99B
est: 19.46B (-17.8%)
21.66B
est: 20.63B (+5.0%)
16.53B
est: 21.93B (-24.7%)
12.62B
est: 23.05B (-45.3%)
31.90B
est: 25.63B (+24.4%)
31.41B
est: 27.91B (+12.5%)
40.99B
est: 31.14B (+31.6%)
15.21B
est: 13.33B (+14.1%)
4.96B
est: 15.82B (-68.6%)
16.76B
16.76B – 16.76B
+6.0% YoY
17.82B
17.82B – 17.82B
+6.3% YoY
18.73B
18.73B – 18.73B
+5.1% YoY
20.82B
20.82B – 20.82B
+11.2% YoY
22.68B
22.68B – 22.68B
+8.9% YoY
25.30B
25.30B – 25.30B
+11.6% YoY
Net Income
3.96B
-10.96B
est: 8.69B (-226.1%)
3.62B
est: 8.69B (-58.4%)
5.91B
est: 8.56B (-31.0%)
6.26B
est: 8.80B (-28.8%)
-4.89B
est: 7.57B (-164.6%)
19.59B
est: 11.23B (+74.4%)
10.88B
est: 13.39B (-18.7%)
14.03B
est: 15.98B (-12.2%)
10.26B
6.90B
est: 9.22B (-25.1%)
9.08B
9.08B – 9.08B
-1.5% YoY
9.34B
9.34B – 9.34B
+2.8% YoY
8.03B
8.03B – 8.03B
-14.0% YoY
11.91B
11.91B – 11.91B
+48.4% YoY
14.20B
14.20B – 14.20B
+19.2% YoY
16.95B
16.95B – 16.95B
+19.4% YoY
SGA
23.11B
est: 44.98B (-48.6%)
47.44B
est: 53.35B (-11.1%)
36.64B
est: 53.35B (-31.3%)
57.54B
est: 56.55B (+1.8%)
63.57B
est: 60.12B (+5.7%)
82.12B
est: 63.19B (+30.0%)
89.37B
est: 70.25B (+27.2%)
82.46B
est: 76.51B (+7.8%)
89.80B
est: 85.35B (+5.2%)
23.94B
est: 39.24B (-39.0%)
28.15B
est: 46.54B (-39.5%)
49.32B
49.32B – 49.32B
+6.0% YoY
52.44B
52.44B – 52.44B
+6.3% YoY
55.12B
55.12B – 55.12B
+5.1% YoY
61.28B
61.28B – 61.28B
+11.2% YoY
66.74B
66.74B – 66.74B
+8.9% YoY
74.45B
74.45B – 74.45B
+11.6% YoY
EPS
233.00
-644.00
est: 472.00 (-236.4%)
203.00
est: 472.00 (-57.0%)
321.00
est: 465.00 (-31.0%)
344.00
est: 478.00 (-28.0%)
-269.00
est: 411.00 (-165.5%)
1,076.32
est: 610.00 (+76.4%)
597.00
est: 727.00 (-17.9%)
771.00
est: 868.00 (-11.2%)
557.00
375.42
est: 472.00 (-20.5%)
465.00
465.00 – 465.00
-1.5% YoY
478.00
478.00 – 478.00
+2.8% YoY
411.00
411.00 – 411.00
-14.0% YoY
610.00
610.00 – 610.00
+48.4% YoY
727.00
727.00 – 727.00
+19.2% YoY
868.00
868.00 – 868.00
+19.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-19 B+ 3/5 1/5 4/5 4/5 2/5 3/5 4/5
2026-05-18 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-15 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-14 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-13 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-12 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-11 B 3/5 1/5 3/5 4/5 2/5 2/5 4/5
2026-05-08 C+ 2/5 1/5 2/5 3/5 1/5 2/5 4/5
2026-05-07 C+ 2/5 1/5 2/5 3/5 1/5 2/5 4/5
2026-05-06 C+ 2/5 1/5 2/5 3/5 1/5 2/5 4/5
2026-05-04 C+ 2/5 1/5 2/5 3/5 1/5 2/5 4/5
2026-04-30 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-29 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-28 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-27 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-24 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-23 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-22 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-21 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-20 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-17 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-16 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-115.41B
OE per share TTM
-6,393.13
Owner's Yield
-59.27%
Maintenance CapEx ratio
264.73%
Maint CapEx / Avg PPE
60.1%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 13 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Kodex KOSPI 226490.KS 0.01% 49.1K 0.15%
2 Dimensional - Emerging Markets Value ETF DFEV 0.00% 25.8K 0.46%
3 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 73.8K 0.39%
4 Dimensional World ex U.S. Core Equity 2 ETF DFAX 0.00% 39.3K 0.28%
5 Avantis Emerging Markets Equity ETF AVEM 0.00% 45.9K 0.33%
6 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 10.9K 0.29%
7 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.00% 13.3K 0.06%
8 Dimensional - Emerging Markets ex China Core Equity ETF DEXC 0.00% 223.67 0.56%
9 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.00% 179.14 0.44%
10 Vanguard FTSE Developed All Cap ex U.S. Index ETF (CAD-hedged) VEF.TO 0.00% 148.80 0.22%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
7.79M
Shares Outstanding
17.93M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Dong-Yeon Kim Chief Executive Officer, President & Director — male
Kyu-Young Choi MD & Director — male
Yoo-Suk Jung Senior MD & Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic